This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, H. Articles by Hellstrom, I. Search for Related Content PubMed PubMed Citation Articles by Zhang, H. Articles by Hellstrom, I.

¹ Department of Pathology and ² Tumor Vaccine Group, Center for Translational Medicine in Women's Health, University of Washington, Seattle, Washington

Requests for reprints: Ingegerd Hellstrom, Box 35 99 39 Harborview Medical Center, 325 Ninth Avenue, Seattle, WA 98104-2499. Phone: 206-341-4707; Fax: 206-726-0302. E-mail: ihellstr{at}u.washington.edu

Tumor-destructive immune responses can be generated by engaging CD137 (4-1BB) via infusing a monoclonal antibody specific for CD137 or vaccinating with a single-chain Fv (scFv) CD137-expressing whole-cell tumor vaccine. We assessed whether such a vaccine can induce tumor rejection in the neu-transgenic (neu-Tg) mouse breast cancer model and compared the antitumor efficacy of vaccination with the infusion of a CD137-specific antibody. Mammary carcinoma cells (MMC) from a neu-Tg mouse were transfected to stably express surface scFv derived from the anti-CD137 rat hybridoma 1D8 or 3H3. The anti-CD137 scFv-expressing cells were rejected when transplanted into neu-Tg mice by a mechanism that involved both CD4⁺ and CD8⁺ T cells, and vaccination with such cells delayed the outgrowth of MMC cells transplanted 3 days previously. T cells from neu-Tg mice that had been vaccinated proliferated and produced IFN- when stimulated by MMC but not by antigen-negative variant breast cancer cells that did not express the neu tumor antigen. In addition, antibodies binding to the MMC but not to antigen-negative variant cells were detected in sera from some but not all of the immunized mice. Complete regression of s.c. transplanted MMC tumors was observed in mice repeatedly immunized against MMC-1D8 starting on the day the MMC cells were transplanted. In contrast, repeated administration of either of two different anti-CD137 monoclonal antibodies did not induce complete tumor regression, although tumor growth was delayed. [Mol Cancer Ther 2006;5(1):149–55]

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: M.L. Disis and I. Hellstrom contributed equally to this work.

³ Yang et al., unpublished findings.

⁴ K. Knutson, unpublished findings.

⁵ Unpublished data.

Received 6/20/05; revised 10/31/05; accepted 11/15/05.

This article has been cited by other articles:

				H. Xiao, B. Huang, Y. Yuan, D. Li, L.-F. Han, Y. Liu, W. Gong, F.-H. Wu, G.-M. Zhang, and Z.-H. Feng Soluble PD-1 Facilitates 4-1BBL-Triggered Antitumor Immunity against Murine H22 Hepatocarcinoma In vivo Clin. Cancer Res., March 15, 2007; 13(6): 1823 - 1830. [Abstract] [Full Text] [PDF]

				Y. Yang, S. Yang, Z. Ye, J. Jaffar, Y. Zhou, E. Cutter, A. Lieber, I. Hellstrom, and K. E. Hellstrom Tumor Cells Expressing Anti-CD137 scFv Induce a Tumor-Destructive Environment Cancer Res., March 1, 2007; 67(5): 2339 - 2344. [Abstract] [Full Text] [PDF]